It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Targeted Protein Degradation (TPD) is an innovative drug discovery approach focused on previously considered ‘undruggable’ proteins. TPD leverages the cell’s ubiquitin-proteasome system to tag these ‘undruggable’ proteins for degradation. Our scientists are harnessing this natural ‘tagging’ system to break down persistent disease-driving proteins.
Targeted protein degradation relies on bringing a ubiquitin ligase into close proximity with a target protein.
As such, this modality does not depend on the target protein having a well-defined and accessible active site or functional binding pocket. Affinity screening methods based on ASMS or DEL approaches can identify ligands that bind to any accessible pocket on the target protein.
But not all proteins are the same and not all protein targets are easily degraded. What if you could rapidly assess the feasibility of a degrader project for your protein of interest?
Our CHARMED platform delivers fast, combinatorial degrader discovery. CHARMED delivers rapid synthesis, screening and characterization of potential bifunctional leads. Ready -to-couple plates of diverse linkers and commonly used ligase warheads accelerate the identification of degrader hits for novel targets.
With CHARMED, you can achieve rapid feasibility assessment through:
Rapid feasibility of degrading a target using two common ligases
Ready-to-couple 96 well plates of ligase warheads attached to linkers
Parallel synthesis of bifunctional PROTAC® degrader compounds
In stock collection of novel linkers and ligase ligands for lead optimization
HTRF®, AlphaLISA® or Jess-system degrader assays for endogenous targets
Engineered live-cell kinetic degradation assays
High throughput in vitro ADME assessment
Why Choose Sygnature Discovery for TPD Support?
Sygnature Discovery has experience in designing, testing and evaluating targeted protein degraders, supported by expertise in the ubiquitin system and protein degradation biology. Our computational and medicinal chemistry, hit-finding capabilities including HTS and fragment -based screening, and disease area breadth make us a strong partner for targeted protein degradation.
TPD programs bring DMPK and pharmacokinetics complexity, understanding degrader effects in the human body as early as possible, can pay dividends, and our skills and solutions in these areas are built to support that need.
Sygnature Discovery successfully identifies potent SHP2 degrader compounds using its proprietary targeted protein degrader platform, CHARMED, in collaboration with Japanese speciality chemical company, UBE Corporation
Read our recent press release to find out how Japanese specialty chemical company, UBE Corporation, has been collaborating with the team at Sygnature Discovery.
Simon Hirst
Chief Executive Officer
Our team
Our Targeted Protein Degradation lead
Roland Hjerpe, PhD
Senior Principal Scientist – Induced Proximity Therapeutics (IPT)
Dr. Roland Hjerpe is a drug discovery expert in Targeted Protein Degradation (TPD), with extensive expertise in protein homeostasis and ubiquitin biology. He has over 20 years of experience spanning academia and industry, including research roles at the Universities of Glasgow and Dundee. Dr. Hjerpe has played a key role… Read More
The concept of Targeted Protein Degradation (TPD) covers all techniques that exploit the natural mechanisms of cellular degradation to target a disease-causing protein for destruction.
